CED Life Science Conference 2017 - Innovation Room
Sub-sector: Biotech and Pharmaceutical
Year Founded: 2016
BetaBlue is an early stage biopharmaceutical company seeking to commercialize functionally selective ligands for the D2 dopamine receptor with the goal of improved efficacy in treating the negative and cognitive symptoms of schizophrenia. We are also pursing development for additional indications, including bipolar disorder, depression, levodopa-induced dyskinesia, childhood dystonia, and addiction disorders.
Jeremy Ollerenshaw PhD, Chief Executive Officer
Jeremy Ford MD MBA, Chief Innovation Officer
Stephen Montgomery PhD, Chief Development Officer
KEY MILESTONES TO DATE
- Company Founded by Jeremy Ford and Jeremy Ollerenshaw, June 2016
- Option for Co-Exclusive License obtained from UNC-Chapel Hill, August 2016
- Preparation of STTR and Michael J. Fox Foundation Grant Applications, September-November 2016
- Recruitment of Stephen Montgomery, PhD, who has overseen the submission of multiple IND applications and previously worked for the FDA, November 2016
Learn more about the CED Life Science Conference.